Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03757351 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03757351 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 15 participants.
The verdict
NCT03757351, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design
Interventions
- DRUG Placebo
- DRUG DNL747
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2020-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03757351
The ClinicalTrials.gov registry entry for NCT03757351 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03757351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03757351 about?
NCT03757351 is a clinical study titled "Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design
What is the current status of trial NCT03757351?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-12-14. Estimated completion is 2020-06-18.
What interventions are being tested in trial NCT03757351?
The interventions under investigation include: Placebo (DRUG), DNL747 (DRUG).
Who is sponsoring clinical trial NCT03757351?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.